Pharmaceutical Sector

Planned Parenthood terms raid by Texas Office of Inspector General as politically motivated

Planned Parenthood terms raid by Texas Office of Inspector General as politicall

Planned Parenthood clinics in Houston, Dallas, and San Antonio witnessed a raid from agents from the Texas Office of the Inspector General who arrived there Thursday morning for getting documents related to allegations of Medical fraud.

The agents stayed there for many hours and gave the administrators 24 hours to provide them with the documents. Planned Parenthood thinks that the raid was 'politically motivated'. Planned Parenthood of the Texas Capital Region Chief Executive Officer Ken Lambrecht said that Texas has asked for information, which as per the organization is not required.

23andMe revamps its website to make genetic information easier to understand

23andMe revamps its website to make genetic information easier to understand

23andMe, a genetic testing company, became a Silicon Valley sensation by giving consumers health and ancestry information based on their saliva sample, but it hit a setback in 2013 when the Food and Drug Administration told it to halt providing health data.

Two years after the ban, now 23andMe has announced that it is going to start providing customers with health information again, though quite less than before and with FDA approval.

The company is hopeful the information related to the risk of passing certain inherited diseases to one’s children is going to reignite growth in its subscriptions. The company is just evolving from being just a consumer testing service into a drug developer.

Clinton requests US Regulators to combat Pharmaceutical Industry’s anticompetitive practices

Clinton requests US Regulators to combat Pharmaceutical Industry

Noticing the egregious actions of Turing Pharmaceuticals, Democratic presidential candidate Hillary Clinton has asked the Food and Drug Administration and the Federal Trade Commission to find out how they can market generic drugs more swiftly and end anticompetitive practices being adopted in pharmaceutical industry.

Turing Pharmaceuticals has increased the price of Daraprim meant for the treatment of a dangerous parasitic infection. The 62-year-old treatment’s price has been raised from $13.50 to $750 a tablet. This step of the company has attracted criticism from Clinton last month.

Shire planning to respond to FDA with OPUS-3 Trial

Shire planning to respond to FDA with OPUS-3 Trial

In an announcement Shire plc said that the company has been asked by the US Food and Drug Administration (FDA) for an additional clinical study in a complete response letter (CRL) to its new drug application for lifitegrast. The drug is used for the signs and symptoms of dry eye disease in adults.

Recently, the company has completed a Phase 3 study of lifitegrast, OPUS-3, that will likely be the basis of response of Shire to the CRL. The FDA has also asked for more information about the product quality, which Shire is going to address in the CRL response.

Before the end of this year, the Topline results of OPUS-3 are expected. It they come positive then the company will submit the data to the FDA as part of a resubmission in the first quarter of 2016.

Dole issues a recall on bagged spinach in 13 states

Dole issues a recall on bagged spinach in 13 states

Food Company Dole issued a recall on bagged spinach in 13 states in the Midwest, South, and on the East Coast on Wednesday morning. As per the Food & Drug Administration, the recall has been issued after a sample of the spinach was tested positive for salmonella.

In case you have recently purchased spinach from Dole and are worried that the recall might affect you, all you need to do is check the bag product code, present on the top right corner of the package, and see if it is either A27409B or A27409A or not.

The likely infected product has an ‘Enjoy By’ date of October 15. Its UPC number is 7143000976. The UPC code is present on the back under the bar code. Precaution is better than cure, so you must go through the bag closely before enjoying spinach.

Aristada gets go-ahead from FDA

Aristada gets go-ahead from FDA

On Monday, the Food and Drug Administration gave permission to Alkermes PLC’s schizophrenia treatment. The drug Aristada will be available in monthly and six-week dosing options. The company wants to introduce the drug immediately.

Aristada is in injectable form of Abilify developed by Japanese drugmaker Otsuka Pharmaceuticals and sold by Bristol-Myers Squibb in the US. It is available as once-a-day oral medication.

Schizophrenia is a serious, disabling brain disorder that affects around 1% of the US population. Patient suffering from it often suffer from psychotic experiences, including hallucinations and delusions. Aristada is not meant to treat patients with dementia-related psychosis.

Lemony Snicket and Lisa Brown Pledge $1 Million to Planned Parenthood

Lemony Snicket and Lisa Brown Pledge $1 Million to Planned Parenthood

Author of a number of children’s book Lemony Snicket said that he and his wife are donating $1 million to Planned Parenthood. Lemony Snicket whose original name is Daniel Handler, made the announcement this week on his Twitter feed.

Snicket on his Twitter feed, @DanielHandler wrote that the donation to the women’s health care provider is o behalf of him and his wife. He said that they’ve been very fortunate and thought this good fortune should be shared with noble causes.

It is known that the house Republicans in Washington have been trying hard to cut off federal funding for Planned Parenthood and have threatened a government shutdown over the issue.
They cite Planned Parenthood’s practice of supplying tissue from aborted fetuses for scientific research.

Roche’s Atezolizumab could be beneficial for Lung, Bladder Cancer Patients

Roche’s Atezolizumab could be beneficial for Lung, Bladder Cancer Patients

Swiss global health-care company Roche announced that its new immune-system boosting cancer drug, atezolizumab, could soon win regulatory approval as the drug has given positive results in tests. On Sunday, the company released data at the European Cancer Congress in Vienna and said that the drug could help people suffering from lung and bladder cancers.

Donald Trump slams Martin Shkreli

Donald Trump slams Martin Shkreli

Martin Shkreli, founder and CEO of Turing Pharmaceuticals, has been slammed by businessman and Republican presidential candidate Donald Trump for hiking up price of a 62-year-old drug, Daraprim.

On Wednesday, in a press conference held in South Carolina, Trump campaigned for the whole day and also gave statements on different issues, together with the most recent controversies in the pharmaceutical industry.

He was asked about his opinion about Martin Shkreli. Trump said in response that he is like a 'spoiled brat' and that he thinks of him as 'hot stuff', especially during the beginning of the week when he was inclined towards controversies.

AbbVie Plans to Move ABT-494 into Late-Stage Trials by End Of 2015

AbbVie Plans to Move ABT-494 into Late-Stage Trials by End Of 2015

AbbVie Inc, a research-based pharmaceutical company, said one of its experimental drugs has improved symptoms of rheumatoid arthritis in mid-stage studies. The company now has scrapped its plan to buy rights to a similar treatment from Belgium's Galapagos NV.

The positive results from the phase-2 trial and the company's decision to move the drug into phase 3 indicates that it is all prepared to maintain its market share even after Humira's patent expires at the end of 2016.

AbbVie's Humira has been the world's best-selling drug since years. Its best-in-class status is due to its widespread use in the treatment of rheumatoid arthritis, an autoimmune disease that affects almost 1.3 million Americans.

‘Entresto’ Recommended For Approval by European Medicines Agency's Review Body

‘Entresto’ Recommended For Approval by European Medicines Agency's Review Body

Novartis AG, a Swiss multinational pharmaceutical company based in Basel, Switzerland, revealed that its new heart failure drug, Entresto, has been recommended for approval in Europe by the European Medicines Agency's review body.

The decision made by Committee for Medicinal Products for Human Use has send Entresto more closer to get approval for heart failure and reduced ejection fraction (HFrEF) patients across Europe by year-end, the company said.

Entresto, which is also known as LCZ696, is the first new drug in decades that claims to help patients whose lives are in danger because their hearts cannot pump blood efficiently. The drug is expected to be one of the biggest new drugs launched in 2015.

DREAM Challenge’s mission to find most synergistic cancer drug combinations reaches a step closer to reality

DREAM Challenge’s mission to find most synergistic cancer drug combinations

Thanks to AstraZeneca’s release of preclinical data from more than 50 medicines, the DREAM Challenge’s mission of finding the most synergistic cancer drug combinations has reached a step closer to reality.

An open innovation competition, the DREAM Challenge, is an established crowd sourcing initiative to examine fundamental questions in biology and medicine. It is based on the making of computer models that can recognize the properties of drugs, making them powerful in combination.

The release of a data set of this scale in public is extraordinary, and is planned in a way to help advance research into combination cancer therapy around the global scientific community.

Plan for price hike of a critical drug to treat rare tuberculosis has been reversed

Plan for price hike of a critical drug to treat rare tuberculosis has been rever

Keeping in mind the outrage over the huge price hike for older drugs like Daraprim, a plan for the purchase and massive price increase of a critical drug for the treatment of rare tuberculosis has been reversed.

Cycloserine was earlier known under the brand name Seromycin. Developed in 1955, it is considered as an 'orphan' drug, which is a special category of medications to treat rare diseases. In this particular case, to treat an odd, stubborn and life-threatening multi-drug resistant tuberculosis (MDR TB) which doesn't respond to the two first tuberculosis treatment drugs.

In August, Rodelis Therapeutics purchased the rights to Cycloserine from a non-profit named The Chao Center, which belongs to Purdue Research Foundation that targets small-batch rare and orphan pharmaceuticals.

Martin Shkreli lowers price of parasitic infection drug

Martin Shkreli lowers price of parasitic infection drug

Turing Pharmaceuticals' chief executive, Martin Shkreli, has made an announcement regarding decreased price of Daraprim, a drug that is used for treatment of a parasitic infection. The company had hiked the cost of a pill from $13.50 to $750. The new price has not been revealed by him, however, it would be below $750 a pill.

Former hedge fund manager Martin Shkreli was slammed after the price of the drug was raised.

Shkreli said, "We've agreed to lower the price on Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit. We think these changes will be welcomed".

Gilead Sciences Inc edging closer to approval of first drug to fight all forms of hepatitis C

Gilead Sciences Inc edging closer to approval of first drug to fight all forms

Gilead Sciences Inc has reached a step closer to the approval of the first drug to fight all forms of hepatitis C. The drug maker's experimental combination has shown high rates of effectiveness in four late-stage studies.

During the trials, a once-daily, fixed-dose combination of the drugmaker's approved hep C blockbuster, Sovaldi, was evaluated with experimental NS5A inhibitor velpatasvir.

The combination is the drug maker's second single-tablet treatment for the viral infection. Gilead's approved drug Harvoni targets the most common form genotype 1 infections.

Analysts at RBC Capital restate XenoPort’s Stock Rating

Analysts at RBC Capital restate XenoPort’s Stock Rating

Analysts at RBC Capital reaffirmed 'buy' rating of XenoPort's stock, Market Beat reported. The RBC gave its rating in a research note issued on Tuesday. RBC analysts mentioned that they presently have a $10.00 price objective on the biopharmaceutical company's stock.

The biopharmaceutical company XenoPort traded down at 28.08% during midday trading on Tuesday reaching at $4.84. The company's stock had a trading volume of 16,040,672 shares.

XenoPort majorly focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders.

Liver Drug RP103 Fails To Match Its Main Goals in Phase 2b CyNCh Study

Liver Drug RP103 Fails To Match Its Main Goals in Phase 2b CyNCh Study

Raptor Pharmaceutical Corp said it will no more develop its liver drug RP103 after the drug failed to meet the main goal in a second mid-stage study. The disappointing results of the drug wiped out more than third of the company’s market value.

The biopharmaceutical company on Monday said in a statement that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study.

Researchers of the study involving around 169 participants between 8 and 17 years old evaluated the effectiveness and safety of RP103 in children diagnosed with nonalcoholic steatohepatitis (NASH).

Study says Truvada could help prevent HIV

Study says Truvada could help prevent HIV

According to two separate studies, Truvada, the treatment manufactured by Gilead can potentially prevent HIV in individuals at higher risk of developing the infection. On the basis of data presented by both the studies, the pill appears to be working effectively. As per the US Centers for Disease Control and Prevention (CDC), Truvada is likely to reduce the risk of HIV infection by 92%.

In the United States, the Truvada pill was approved for ‘pre-exposure prophylaxis’ (PrEP) of the AIDS – causing HIV – and can decrease the risks of the infection. The treatment is for the people who do not have the virus so far, but even then they are at substantial risk of getting it. The infection can be prevented by taking the treatment every day.

Teva Pharmaceuticals and IBM Partner to look for data health solutions

Teva Pharmaceuticals and IBM Partner to look for data health solutions

It has been announced by IBM Watson Health and Teva Pharmaceutical Industries Ltd. that Teva has been chosen as its first Foundational Life Sciences Partner for the Watson Health Cloud. With this, Teva will be the first global pharmaceutical company to use the power of the Watson Health Cloud to help patients and healthcare providers across the world.

GlaxoSmithKline inhaler trial fails to show prolonged life in patients

GlaxoSmithKline inhaler trial fails to show prolonged life in patients

A clinical trial by GlaxoSmithKline on large scale has failed to prove that Breo Ellipta inhaler of the company extends life in patients suffering from chronic obstructive pulmonary disease. With the failure, hopes of the company regarding the product have shattered.

Glaxo was expecting that Summit study that tested Breo against a placebo in more than 16,000 patients from 43 countries would show that the product extends life and also helps with breathing.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content